The pharmacoepidemiological study of Zonisamide for Parkinson's disease

The pharmacoepidemiological study of Zonisamide for Parkinson's disease - The pharmacoepidemiological study of Zonisamide for Parkinson's disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026890

Enrollment

100000

Registered

2017-04-10

Start date

2017-04-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosed with Parkinson's disease (ICD-10:G20) between April 2008 to December 2012.

Exclusion criteria

Exclusion criteria: 1. Having only sub-category of G20; 3320001, 8830558, 8841415. 2. Secandary Parkinson's diseaase, which is defined as diagnosed with ICD-10 codes of G21, G22, and G23.

Design outcomes

Primary

Measure	Time frame
The incidence and prevalence of comorbidities	—

Secondary

Measure	Time frame
The doses of anti-Parkinson drugs.	—

Countries

Japan

Contacts

Public ContactHirotaka Iwaki

Ehime University Graduate School of Medicine Neurology and Clinical Pharmacology

h-iwaki@m.ehime-u.ac.jp089-960-5095

Outcome results